The New England journal of medicine, 2023-02, Vol.388 (8), p.719-732
- Fizazi, Karim
- Piulats, Josep M.
- Reaume, M. Neil
- Ostler, Peter
- McDermott, Ray
- Gingerich, Joel R.
- Pintus, Elias
- Sridhar, Srikala S.
- Bambury, Richard M.
- Emmenegger, Urban
- Lindberg, Henriette
- Morris, David
- Nolè, Franco
- Staffurth, John
- Redfern, Charles
- Sáez, María I.
- Abida, Wassim
- Daugaard, Gedske
- Heidenreich, Axel
- Krieger, Laurence
- Sautois, Brieuc
- Loehr, Andrea
- Despain, Darrin
- Heyes, Catherine A.
- Watkins, Simon P.
- Chowdhury, Simon
- Ryan, Charles J.
- Bryce, Alan H.
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Fizazi, Karim
- Piulats, Josep M.
- Reaume, M. Neil
- Ostler, Peter
- McDermott, Ray
- Gingerich, Joel R.
- Pintus, Elias
- Sridhar, Srikala S.
- Bambury, Richard M.
- Emmenegger, Urban
- Lindberg, Henriette
- Morris, David
- Nolè, Franco
- Staffurth, John
- Redfern, Charles
- Sáez, María I.
- Abida, Wassim
- Daugaard, Gedske
- Heidenreich, Axel
- Krieger, Laurence
- Sautois, Brieuc
- Loehr, Andrea
- Despain, Darrin
- Heyes, Catherine A.
- Watkins, Simon P.
- Chowdhury, Simon
- Ryan, Charles J.
- Bryce, Alan H.
- Titel
- Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
- Ist Teil von
- The New England journal of medicine, 2023-02, Vol.388 (8), p.719-732
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a randomized trial involving men with metastatic prostate cancer with a DNA-repair defect, rucaparib was associated with longer progression-free survival than a control medication (11.2 vs. 6.4 months).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2214676Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10064172
- Format
- –
- Schlagworte
- Acetic acid, Androgen Antagonists - therapeutic use, Antineoplastic Agents - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, BRCA1 protein, BRCA2 protein, Breast cancer, Cancer, Cancer therapies, Castration, Chemotherapy, Clinical outcomes, Clinical trials, Confidence intervals, Disease Progression, Docetaxel - therapeutic use, General Medicine, Genes, BRCA1, Genes, BRCA2, Genetics, Genitourinary Cancer, Hematology, Human health sciences, Humans, Hypothesis testing, Indoles, Indoles - therapeutic use, Kinases, Male, Metastases, Metastasis, Oncologie, Oncology, Patients, Physicians, Poly(ADP-ribose), Poly(ADP-ribose) polymerase, Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use, Population, Progression-Free Survival, Prostate cancer, Prostate Disease, Prostate Disease General, Prostatic Neoplasms, Castration-Resistant - drug therapy, Prostatic Neoplasms, Castration-Resistant - genetics, Prostatic Neoplasms, Castration-Resistant - secondary, rucaparib, Sciences de la santé humaine, Statistical analysis, Survival, Survival analysis, Treatments in Oncology, Urology